MP09-06 PROSTATE CANCER DETECTION AND COMPLICATIONS OF TRANSPERINEAL VERSUS TRANSRECTAL MRI-FUSION GUIDED PROSTATE BIOPSIES

Abstract

Listen

Translate article

You have accessJournal of UrologyCME1 May 2022MP09-06 PROSTATE CANCER DETECTION AND COMPLICATIONS OF TRANSPERINEAL VERSUS TRANSRECTAL MRI-FUSION GUIDED PROSTATE BIOPSIES Dylan Buller, Jessa Sahl, Ilene Staff, Joseph Tortora, Kevin Pinto, Tara McLaughlin, Laura OlivoValintin, and Joseph Wagner Dylan BullerDylan Buller More articles by this author , Jessa SahlJessa Sahl More articles by this author , Ilene StaffIlene Staff More articles by this author , Joseph TortoraJoseph Tortora More articles by this author , Kevin PintoKevin Pinto More articles by this author , Tara McLaughlinTara McLaughlin More articles by this author , Laura OlivoValintinLaura OlivoValintin More articles by this author , and Joseph WagnerJoseph Wagner More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002531.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Detection rates of clinically significant prostate cancer (csPCa) in transperineal (TP) and transrectal (TR) MRI-fusion targeted prostate biopsies (MRI-bx) remains in question. We compared TP and TR approaches on rates of detection of csPCa and complications when performing MRI-bx. METHODS: We retrospectively identified men ages 18-89 who underwent TP or TR MRI-bx with concurrent systematic random biopsy from August, 2020 to August, 2021. Patients undergoing systematic-only TR biopsies were also included. Analyses primarily focused on cancer detection rates between the two MRI-bx groups; comparisons were also made to the standard random biopsy group. Data were additionally stratified by prior biopsy status. Grade Group ≥2 was considered csPCa. Complications within 30 days of biopsy were also compared. RESULTS: 520 patients were included in the analysis. No demographic differences were observed (Table 1). When analyzing only MRI-bx approaches, no significant differences were observed between TP and TR on any of the outcomes of interest (Table 2). TR MRI-bx identified csPCA in 47.2% of patients, and TP MRI-bx identified csPCA in 48.6% of patients (p = 0.777); systematic-only TR biopsies identified csPCA in 34.0% of patients. 50.4% of TR MRI-bx and 54.1% of TP MRI-bx identified csPCa in patients on active surveillance (AS) (p = 0.589). 30.8% of TR MRI-bx and 41.0% of TP MRI-bx identified csPCa in patients with a prior negative biopsy (p = 0.345). 62.5% of TR MRI-bx and 43.8% of TP MRI-bx identified csPCa in biopsy-naïve patients (p = 0.194). Significant differences were observed in csPCa detection between all three approaches for AS (p = 0.013) and prior negative biopsy patients (p = 0.045), but not between MRI-TP and MRI-TR biopsies. CONCLUSIONS: Neither the identification of csPCa by MRI-bx nor rates of complications differed significantly based on a TR or TP approach. No differences were seen between MRI-guided approaches based on prior biopsy/AS status. Source of Funding: Unfunded © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e137 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Dylan Buller More articles by this author Jessa Sahl More articles by this author Ilene Staff More articles by this author Joseph Tortora More articles by this author Kevin Pinto More articles by this author Tara McLaughlin More articles by this author Laura OlivoValintin More articles by this author Joseph Wagner More articles by this author Expand All Advertisement PDF DownloadLoading ...